The George Washington Cancer Institute | Strategic Alliance Partners

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

Mitchell R. Smith, MD, PhD, discusses the results of the ECOG-ACRIN E1411 trial examining BR-based induction treatment in patients with mantle cell lymphoma and next steps for research.

Mitchell R. Smith, MD, PhD, discusses the rationale for the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Mitchell R. Smith, MD, PhD, discusses the results of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Mitchell R. Smith, MD, PhD, discusses the rationale behind the trial looking at the fixed duration of the ibrutinib and venetoclax combination in chronic lymphocytic leukemia.

Mitchell R. Smith, MD, PhD, division director, Cancer and Blood Disorders, and professor of medicine, GW Cancer Center, discusses the use of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

Imad Tabbara, MD, discusses available treatment options for transplant-eligible and -ineligible patients with multiple myeloma.

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia.

Kieron Dunleavy, MD, discusses emerging treatment options and when to use the watch-and-wait approach in follicular lymphoma.

Eduardo Sotomayor, MD, discusses the evolution of CAR T-cell therapy, adverse events that require careful monitoring, and novel strategies under development that may mitigate toxicity and improve T-cell persistence.

Mitchell R. Smith, MD, PhD, discusses the use of chemotherapy versus targeted therapy in patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Mitchell R. Smith, MD, PhD, discusses the potential advantage of lenalidomide in chronic lymphocytic leukemia.

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses the durability of CAR T cells, as well as ways to combat immune escape mechanisms in hematologic malignancies.

Imad Tabbara, MD, discusses the expansion of treatment options for patients with acute myeloid leukemia.

Mitchell R. Smith, MD, PhD, discusses two randomized phase III trials investigating the benefit of ibrutinib-based therapies in patients with chronic lymphocytic leukemia.